(secondQuint)Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma.

 R-GDP has been used to treat many people with lymphoma.

 Ibrutinib has been shown to benefit people with certain types of lymphoma.

 They have not previously been given together.

 This research is being done to try to find new combinations of treatment that may be better for treating patients with this disease.

 It is not clear however if these treatments can offer better results than standard treatment.

 The standard or usual treatment of this disease is treatment with rituximab plus gemcitabine, dexamethasone, and cisplatin (R-GDP).

.

 Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma@highlight

The purpose of this study is to find out what effects new combinations of treatment will have this disease.

 In this clinical trial, the study treatment options currently are ibrutinib plus R-GDP, or R-GDP alone.

